Over the past few months, we've profiled a number of companion diagnostics deals between big biopharmas and diagnostic companies. This week, Denmark's Dako reported it is working with Amgen ($AMGN) on a test for a cancer drug candidate currently in clinical development. Last month, Dako announced a collaboration agreement with Amgen for the development of drug and diagnostics for cancer. "This new collaboration with Amgen underlines Dako's commitment to advance personalized medicine in cancer treatment as the selection of patients most likely to benefit from a specific treatment will increase the probability of therapeutic success for cancer patients suffering," Dako CEO Lars Holmkvist said in a statement. Dako statement